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Abstract 
Background: Progress toward the global target for 95% virological suppression among those on antiretroviral treat-
ment (ART) is still suboptimal. We describe the viral load (VL) cascade, the incidence of virological failure and associ-
ated risk factors among people living with HIV receiving first-line ART in an HIV cohort in Myanmar treated by the 
Médecins Sans Frontières in collaboration with the Ministry of Health and Sports Myanmar.
Methods: We conducted a retrospective cohort study, including adult patients with at least one HIV viral load test 
result and having received of at least 6 months’ standard first-line ART. The incidence rate of virological failure (HIV 
viral load ≥ 1000 copies/mL) was calculated. Multivariable Cox’s regression was performed to identify risk factors for 
virological failure.
Results: We included 25,260 patients with a median age of 33.1 years (interquartile range, IQR 28.0–39.1) and a 
median observation time of 5.4 years (IQR 3.7–7.9). Virological failure was documented in 3,579 (14.2%) participants, 
resulting in an overall incidence rate for failure of 2.5 per 100 person-years of follow-up. Among those who had a 
follow-up viral load result, 1,258 (57.1%) had confirmed virological failure, of which 836 (66.5%) were switched to 
second-line treatment. An increased hazard for failure was associated with age ≤ 19 years (adjusted hazard ratio, aHR 
1.51; 95% confidence intervals, CI 1.20–1.89; p < 0.001), baseline tuberculosis (aHR 1.39; 95% CI 1.14–1.49; p < 0.001), a 
history of low-level viremia (aHR 1.60; 95% CI 1.42–1.81; p < 0.001), or a history of loss-to-follow-up (aHR 1.24; 95% CI 
1.41–1.52; p = 0.041) and being on the same regimen (aHR 1.37; 95% CI 1.07–1.76; p < 0.001). Cumulative appointment 
delay was not significantly associated with failure after controlling for covariates.
Conclusions: VL monitoring is an important tool to improve programme outcomes, however limited coverage of VL 
testing and acting on test results hampers its full potential. In our cohort children and adolescents, PLHIV with history 
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Background
There is a global commitment to end the AIDS epidemic 
by 2030 [1] and the global HIV response has improved 
access to care and survival among people living with 
HIV (PLHIV) [2]. However, by the end of 2018, virologi-
cal suppression for PLHIV on antiretroviral treatment 
(ART) was 85%, which is still below the UNAIDS target 
of 95%. Scale-up of routine HIV viral load (VL) testing 
in resource-limited settings has been suboptimal due to 
the cost and complexity of VL testing, but also due to the 
lack of awareness about the benefits of regular VL moni-
toring among health care providers and patients [3]. In 
2018, UNAIDS reported 49% (95% CI 38–63%) estimated 
rates of virological suppression among all PLHIV in the 
Asia and Pacific region [2].
In 2017, less than 5% of those globally receiving ART 
were thought to be receiving second-line ART [4]. A 
study from sub-Saharan Africa identified poor access 
to HIV VL monitoring as the main reason for a delayed 
switch to second-line treatment. VL monitoring was 
poorly used even when available in this cohort: 40% of 
patients with virological failure were not switched to sec-
ond-line ART, whereas 30% had been switched without 
proof of failure [4]. A study from Myanmar reported high 
rates of virological failure, but low rates of switching to 
second-line treatment [5]. Lack of switching was attrib-
uted to clinical or programmatic factors, such as delayed 
reporting of the VL results, concerns about adherence or 
pill burden, or centralized decision making [6]. The cost 
of second-line treatment, was also prohibitive, being 2.5 
times more expensive than the first-line therapy at the 
time [7]. Improper management of patients with treat-
ment failure leads to poor treatment outcomes, accu-
mulation and transmission of HIV drug resistance and 
increases cost of HIV care delivery [8, 9].
Myanmar has the second highest HIV prevalence in 
Southeast Asia with an estimated 0.57% of the general 
population being HIV-positive [2]. In 2018 there were an 
estimated 240,000 PLHIV in the country with the high-
est HIV burden among sex workers, men having sex with 
men and people who inject drugs [10]. The National 
AIDS Programme achieved 77% ART coverage by the 
end of 2019 [11]. Despite significant improvements in 
access to HIV care and national guidelines recommend-
ing routine HIV VL testing [12], only 72% of PLHIV on 
ART had access to VL monitoring in 2019 in the coun-
try [11]. Virological suppression among those who had 
access to HIV VL testing was 95%, thus it is on track to 
the 95% UNAIDS target [13].
Previous studies identified poor adherence [14–16], 
advanced HIV disease [15–18], tuberculosis co-infection 
[14], and longer time on first-line ART as predictors of 
ART failure [16]. Recent studies reported an association 
between having low-level viremia and virological failure 
[19, 20]. With the increasing life span of the HIV cohorts, 
it is increasingly common for people to interrupt treat-
ment for a short period of time or to be lost-to-follow 
up (LFU) and then re-engage in care. Studies report that 
11–77% of patients enrolled in HIV care temporarily dis-
engage [21–25]. In most HIV programmes the frequency 
of treatment interruptions is very likely underestimated 
by most HIV programmes. HIV care is more complex 
for patients previously exposed to ART and at risk of 
HIV drug resistance, especially if presenting back into 
care with advanced HIV disease [26, 27]. The correlation 
between cumulative appointment delay and treatment 
failure has not been explored in any previous studies, to 
our knowledge.
Since 2003 Médecins Sans Frontières (MSF) has been 
providing HIV care in Yangon, Kachin and Shan States. 
VL monitoring was introduced in 2009, initially as a tar-
geted approach for those most at risk of failure. Since 
2016 all patients were eligible for routine HIV VL moni-
toring once per year. In this study we describe the VL 
cascade, the incidence of virological failure and associ-
ated risk factors, including the cumulative appointment 
delay, among PLHIV receiving first-line ART in the HIV 
cohort treated by MSF in Myanmar.
Methods
Design and study population
We conducted a retrospective cohort study of patients 
enrolled on ART in the MSF HIV programme in Myan-
mar between 01 January 2001 and 31 October 2017. The 
study included patients who had at least one HIV VL test 
available after receiving at least 6  months of standard 
first-line ART (Fig. 1).
Study setting
The study was conducted in the MSF HIV programmes 
in Yangon, Kachin and Shan States in Myanmar. The 
study sites provided a comprehensive package of HIV 
care free of charge. Clinical care was provided by medi-
cal doctors and nurses, while trained counselors and 
of loss-to-follow-up or those with low-viremia are at the highest risk of virological failure and might require more 
frequent virological monitoring than is currently recommended.
Keywords: HIV, First-line antiretroviral treatment, Virological failure, Lost-to-follow up, Low viremia, Myanmar
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outreach adherence supporters provided counselling 
and adherence support [28]. Since 2009 HIV VL test-
ing targeted those with immunological and/or clini-
cal failure, and those switching their first-line regimen 
because of modified guidelines. From 2014 onwards, 
yearly routine VL monitoring targeted all children and 
patients on second-line ART. Since 2016, yearly rou-
tine VL testing was introduced for all patients on ART. 
Patients with viremia (VL > 200 copies/mL defined as 
a limit of detection) received 3–6 counselling sessions 
over a period of 3  months and were then prescribed 
a follow-up VL test. Those with two consecutive VL 
results above the threshold for failure (≥ 5000 cop-
ies/mL until 2012,  ≥ 1000 copies/mL after 2012) were 
started on a second-line ART regimen. If the follow-up 
VL did not show failure, enhanced adherence support 
continued together with three-monthly VL monitoring 
until undetectable viremia was observed.
For the first-line treatment a combination of two 
nucleoside/nucleotide reverse transcriptase inhibi-
tors (zidovudine, tenofovir, lamivudine, abacavir) with 
a non-nucleoside reverse transcriptase inhibitor (efa-
virenz or nevirapine) was used. Second-line regimen 
was composed of two nucleoside/nucleotide reverse 
transcriptase inhibitors, ideally not used in the first-line 
regimen and one protease inhibitor (atazanavir/ritona-
vir or lopinavir/ritonavir).
Study variables
The study used routine programme data collected from 
standardized patient forms and encoded in the MSF 
HIV programme database, FUCHIA (Follow-up and 
Care of HIV Infection and AIDS). Values recorded dur-
ing the ART initiation visit were considered baseline for: 
age, marital status, gender, World Health Organization 
(WHO) stage, body mass index (BMI), risk group, and 
tuberculosis co-infection. We defined CD4 at ART ini-
tiation as the measurement taken closest to the date of 
ART initiation, within 92 days before or after initiation. 
BMI was used as a binary variable (< 18.5 kg/m2,  ≥ 18 kg/
m2) and values > 40  kg/m2 were considered errors and 
defined as missing. Yearly coverage of viral load was 
defined as the proportion of patients active and in care 
at the end of the year, who had at least one VL measure-
ment in that year. Virological failure was defined as a 
patient with a VL ≥ 1000 copies at a visit ≥ 183 days after 
ART initiation. Those with a follow-up VL ≥ 1000 copies/
ml, within 183  days of a previous VL showing virologi-
cal failure, had confirmed virological failure. Low-level 
viremia was defined as a VL between 200 and 999 copies, 
Fig. 1 Flowchart of inclusion pathway in the study
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occurring ≥ 183  days after ART initiation, and prior to 
a first episode of virological failure. Starting dates were 
defined for each patient based on the earliest visit date at 
which ART was prescribed. If this date was before 2009, 
then the start date was set to 1st January 2009 for regres-
sion analyses. The reason for this is that VL testing only 
started to become widely available after 2009; thus, the 
need to avoid overweighting those who started treat-
ment before 2009 but had no chance of having VL tests. 
For calculation of operational indicators in the cascade 
analysis, the original ART start date was used, regardless 
of whether this was before 2009 or not. End dates were 
defined based on the earliest occurring visit date at which 
there was either a virological failure, death, switch to 
second line ART or reached the maximum visit for that 
patient without event. For the definition of LFU, each 
visit had an expected next visit date. We calculated the 
difference between expected and actual next visit date 
in days. If this difference was greater than 60 days then 
the earlier visit was marked as LFU. Using this, the fol-
lowing variables were created: number of times a patient 
was LFU, total days patient was LFU (including the ini-
tial 60  days). Cumulative appointment delay was calcu-
lated as the number of days of delay between the dates of 
appointment and the actual dates visits took place. Time 
under observation was calculated as the time between 
starting and ending dates in years. Time on ART was cal-
culated as time under observation minus time LFU.
Data analysis
Baseline characteristics were described using frequencies 
and percentages for categorical variables and medians 
with interquartile ranges (IQRs) for continuous variables. 
We compared proportions for categorical variables using 
a chi-squared test (with Holm correction) and differences 
in distribution for continuous variables using a Kruskal–
Wallis test. The purpose of this was to both describe the 
cohort and to roughly estimate selection bias. The inci-
dence rate for virological failure was calculated as the 
number of patients with a first VL ≥ 1000 copies over 
the total observation time. Using Cox proportional haz-
ard regressions, we computed hazard ratios (HR) and 
respective 95% confidence intervals (CI). Significant 
variables from the bivariable analyses were investigated 
for confounding and effect modification using Mantel–
Haenszel statistics and Woolf ’s tests, as well as testing 
for co-linearity. Only dichotomized versions of variables 
were included in multivariable analyses. Variables were 
selected for multivariable analysis based on results from 
bivariable and stratified analyses. Where effect modi-
fication was identified in stratified analysis, we tested 
whether the addition of interaction terms significantly 
improved the model fit based on Akaike information 
criterion and analysis of variance. Only complete cases, 
thus without missing information for any of the variables 
selected in the univariate analysis, were considered for 
multivariable analysis. The final multivariable model was 
selected based on step-wise forward and backward Cox 
proportional hazards regression using the Akaike infor-
mation criterion and likelihood ratio tests. The model 
proportional hazards assumption was tested using scaled 
Schoenfeld residuals. Assumptions of non-linearity was 
assessed visually. All analyses were two-tailed, with a sig-
nificance level of 0.05, and carried out using R statistical 




As illustrated in the Fig. 1, during the period 2003–2017 
there were 51,010 patients enrolled in MSF programmes. 
5,873 (11.5%) patients in the cohort were LFU or died 
before ART was initiated. Among patients who started 
on ART, 35,356 (78.3%) received > 6  months standard 
first line treatment. Among the 35,356, there were 7,858 
(22.2%) who initiated treatment before 2009, before VL 
monitoring was implemented; and 27,498 (77.8%) initiat-
ing treatment during or after 2009. Among the 35,356, we 
recorded 140,779 person-years of follow-up time. During 
this time, 25,260 (71.4%) patients had at least one HIV 
VL test result available. HIV VL test coverage increased 
over time, with below 10% of individuals having a visit in 
2013 and a VL test during the same year, to 57% in 2017 
(Fig. 2).
Patients may have had multiple visits and multiple tests 
in one year however only the first result in a specific year 
was considered. A patient is included in the total count 
of each year they were receiving ART for at least part of 
the year.
Baseline characteristics
Baseline characteristics of the first-line cohort, strati-
fied by having received an HIV VL test, are presented in 
Table 1. Among 25,260 patients included in the analysis 
of virological outcomes, the median age was 33.1  years 
(IQR 28.0–39.1) and 54.7% were male. The median obser-
vation time was 5.4 years (IQR 3.7–7.9). The median CD4 
count was 143 cells/mL (IQR 55–264) in 10,236 patients 
tested. Nearly half (45.6%) presented with WHO stage III 
or IV disease. Approximately one in four of this cohort 
(n = 6,656; 26.4%) were diagnosed with tuberculosis at 
baseline. Overall, 9,861 (39.0%) patients had one epi-
sode of low-level viremia and in 2,438 (24.7%) patients 
this occurred more than once. There were 2,440 (9.7%) 
patients LFU at least once, and 419 (1.66%) more than 
once. Most patients (86.7%, n = 21,918) were late at least 
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once for a scheduled appointment. When considering 
delays to all scheduled appointments in total, about one 
in four (n = 6,005, 23.8%) had a cumulative appointment 
delay greater than 60 days.
Comparison between patients who did or did not have 
at least one HIV VL test showed that those who had HIV 
VL test results tended to be younger (median 33.1 years 
vs. 34.1 years; p < 0.001), had been on ART after 2009 for 
a longer time (median 5.4 years vs. 2.8 years, p < 0.001), 
and tended to have lower CD4 counts at ART initiation 
(median 143 cells/mL vs. 189 cells/mL; p < 0.001). Base-
line tuberculosis was diagnosed more frequently among 
those who received HIV VL testing (24.8 vs. 20.7%; 
p < 0.001) and a lower proportion of them had a history of 
LFU (10.9 vs. 14.0%; p < 0.001). History of injecting drug 
use was less frequently reported among those with access 
to viral load testing (5.8 vs. 7.9%; p < 0.001). Those who 
had access to HIV VL testing had more episodes of late 
appointments, but a lower cumulative number of days 
late, and only 25% of them accumulated ≥ 60 days late for 
appointments, in comparison with 28.2% of those who 
had never received a HIV VL test (p < 0.001).
HIV VL cascade
Of 25,260 patients with at least one VL test result avail-
able, 3579 (14.2%) had documented virological failure, 
with a calculated incidence of failure of 2.5 per 100 per-
son-years (3579 patients with failure during 143,160 years 
of follow-up). Among those with virological failure, 2202 
(61.5%) had a consecutive VL test within six months of 
the first test that showed virological failure (Fig.  3). Of 
those with a consecutive VL test 1258 (57.1%) individu-
als had confirmed virological failure. Among those with 
confirmed virological failure, 836 (66.5%) switched to 
Fig. 2 Number of people with at least one visit per year, categorized by receipt of at least one viral load test result in the same year
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Table 1 Baseline characteristics of the first-line cohort by receipt of HIV VL testing (n = 35,356)
*Chi2 test with Holm correction
Variable Value Total (n = 35,356) (%) HIV VL test result not 
available (n = 10,096)




Age at ART initiation > 19 years 32,387 91.6 9774 96.8 22,613 89.5  < 0.001
Gender (Female) 15,749 44.5 4294 42.5 11,455 45.3 0.02
Divorced 10 0.0 8 0.1 2 0.0 0.108
Married 20,165 57.0 6190 61.3 13,975 55.3  < 0.001
Separated 2178 6.2 673 6.7 1505 6.0 0.363
Single 8163 23.1 2010 19.9 6153 24.4  < 0.001
Widow 3927 11.1 1058 10.5 2869 11.4 0.409
Man who has sex with men 250 0.7 55 0.5 195 0.8 0.437
History of injection drug use 2785 7.9 1331 13.2 1454 5.8  < 0.001
History of sex work 508 1.4 120 1.2 388 1.5 0.37
History of blood transfusion 584 1.7 143 1.4 441 1.7 0.482
Economic migrant 675 1.9 241 2.4 434 1.7 0.053
History of imprisonment 515 1.5 169 1.7 346 1.4 0.498
Displaced person 106 0.3 41 0.4 65 0.3 0.434
Having HIV + partner 1902 5.4 760 7.5 1142 4.5  < 0.001
Baseline body mass index < 18.5 kg/m2 6829 19.3 1592 15.8 5237 20.7  < 0.001
Missing 21,289 60.2 6091 60.3 15,198 60.2
Baseline WHO stage 1 11,501 32.5 3426 33.9 8075 32.0  < 0.001
2 1108 3.1 261 2.6 847 3.4
3 9710 27.5 2406 23.8 7304 28.9
4 5516 15.6 1336 13.2 4180 16.5
Missing 7521 21.3 2667 26.4 4854 19.2
Baseline Tuberculosis 8754 24.8 2088 20.7 6666 26.4  < 0.001
Baseline CD4 (cells/mL)  < 200 8434 23.9 2013 19.9 6421 25.4  < 0.001
200–500 4668 13.2 1,483 14.7 3185 12.6
 > 500 928 2.6 298 3.0 630 2.5
Missing 21,326 60.3 6302 62.4 15,024 59.5
Time on ART (years)  < 2 6773 19.2 4174 41.3 2599 10.3  < 0.001
2 – 5 11,984 33.9 3500 34.7 8484 33.6
 > 5 16,599 46.9 2422 24.0 14,177 56.1
History of no treatment change 11,355 32.1 5411 53.6 5944 23.5  < 0.001
Missing 204 0.6 117 1.2 87 0.3
History of low viremia 9861 27.9 NA NA 9861 39.0
Frequency of low viremia 1 7423 21.0 NA NA 7423 29.4
 ≥ 2 2438 6.9 NA NA 2438 9.7
History of lost-to-follow-up 3850 10.9 1410 14.0 2440 9.7  < 0.001
Number of times lost-to-follow-up 1 3176 9.0 1155 11.4 2021 8.0  < 0.001
2 512 1.4 194 1.9 318 1.3
 ≥ 3 162 0.5 61 0.6 101 0.4
Cumulative appointment delay ≥ 60 days 8852 25.0 2847 28.2 6005 23.8  < 0.001
Cumulative appointment delay (days) 1–59 21,507 60.8 5594 55.4 15,913 63.0  < 0.001
60–181 4492 12.7 1286 12.7 3206 12.7
182–364 1709 4.8 586 5.8 1123 4.4
 ≥ 365 2651 7.5 975 9.7 1676 6.6
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second-line ART within six months since confirmed viro-
logical failure. Among those with confirmed virological 
failure, the median time between the virological failure 
and confirmed virological failure was 3.6  months (IQR 
2.4–4.8) and the median time between ART initiation 
and confirmed virological failure was 3.7  months (IQR 
2.3–5.7).
Predictors of virological failure
Using univariate regression, patients whose marital sta-
tus was single (HR 1.66; 95% CI 1.54–1.78 p < 0.001), 
who were economic migrants (HR 1.63; 95% CI 1.30–
2.05; p < 0.001), those with baseline BMI < 18.5  kg/m2 
(HR 1.38; 95% CI 1.25–1.53; p < 0.001), CD4 > 500 cells/
mL (HR 1.64; 95% CI 1.34–2.00; p < 0.001), or WHO 
stage two (vs. WHO stage one; HR 1.26; 95% CI 1.06–
1.49; p < 0.001) were more likely to have virological fail-
ure (Table  2). Also PLHIV who experienced low-level 
viremia (HR 1.59; 95% CI 1.49–1.79; p < 0.001), were LFU 
at least once (HR 1.80; 95% CI 1.65–1.96; p < 0.001), or 
had a cumulative appointment delay over 60  days (vs. 
those who were never late; HR 1.69, 95% CI 1.58–1.81, 
p < 0.001) were more likely to experience virological fail-
ure. Females (HR 0.86; 95% CI 0.81–0.92; p < 0.001) or 
those with age > 19  years at ART initiation (0.36; 95% 
CI 0.35–0.42; p < 0.001) had lower hazards of virological 
failure.
The multivariable analysis was conducted on 8,308 
patients (32.9%) with complete information for all the 
variables required (Table 3), those presenting with base-
line tuberculosis (aHR 1.39; 95% CI 1.14–1.49; p < 0.001), 
with a history of low-level viremia (aHR 1.60; 95% C I 
1.42–1.81; p < 0.001), a history of LFU (aHR 1.24; 95% 
CI 1.41–1.52; p = 0.041), or being on the same treatment 
regimen since the start of treatment (aHR 1.37; 95% CI 
1.07–1.76; p < 0.001) were associated with an increased 
hazard of failure, while controlling for other covariates. 
Starting ART at the age > 19  years was associated with 
34% lower hazard of failure (95% CI 0.53–0.83; p < 0.001). 
Cumulative appointment delay was not significantly asso-
ciated with failure after controlling for other covariates. 
We observed an interaction between sex work and gen-
der (aHR 2.30; 95% CI 0.54–9.66; p = 0.26) and between 
gender and being single (aHR 1.43; 95% CI 1.08–1.89; 
p = 0.013). The differences between the characteristics of 
the population included in the final regression model and 
the entire population on first-line ART in this cohort, are 
presented in the Additional file 1: Table S1.
Discussion
Our study investigated virological outcomes in PLHIV 
receiving first-line ART in Myanmar. During the long 
observation period, a total of 25, 260 (71.4%) PLHIV 
received at least one VL test and 14.2% experienced viro-
logical failure (2.5 per 100 person-years). Our results are 
comparable with previous reports from resource-limited 
settings, where virological failure occurred in 4.3–34.0% 
PLHIV on first-line ART [14, 15, 29–32]. Previous studies 
from Myanmar reported good long-term immunological 
and virological treatment outcomes among PLHIV on 
treatment [33], with one cohort experiencing a virologi-
cal failure rate of 3.2 per 100 person-years [5]. In general, 
Fig. 3 Viral load testing cascade among the first-line cohort (n = 35,356). The % against each bar are calculated using the total cohort number in 
the above bar as the denominator
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higher virological suppression rates have been reported 
in Asia than in Africa [34], although any comparison of 
virological outcomes is challenging, as local VL moni-
toring guidelines differ, and study follow-up times vary 
between the cohorts.
We showed that the risk of virological failure was lower 
among those initiating ART if they were aged > 19 years 
(90% of the study cohort) compared to those with or 
younger than 19  years. This finding is similar to that 
reported in other studies. The higher risk of failure 
among children and adolescents may be explained by 
suboptimal adherence, lack of paediatric drug formula-
tions, and lack of care models responsive to the specific 
needs of these subgroups [5, 17, 35–37]. Patients in our 
cohort study, with baseline tuberculosis were at higher 
risk of virological failure, consistent with findings from 
Table 2 Crude hazard ratios (HR) for virological failure among PLHIV with more than 6 months of first-line ART and at least one VL test 
(n = 25,260)
*Wald test for the hazard ratio estimate of each exposure variable—comparing counts of those exposed with virological failure to those without







N % N %
Age at ART initiation > 19 years 19,752 87.3 2861 12.7 0.36 (0.35–0.42)  < 0.001
Female 9954 86.7 1501 13.3 0.86 (0.81–0.92)  < 0.001
Divorced NA NA 0 NA
Married 12,295 88.0 1680 12.0 0.71(0.66–0.75)  < 0.001
Separated 1271 84.5 234 15.5 1.90 (0.95–1.23) 0.228
Single 4948 80.4 1205 19.6 1.66 (1.54–1.78)  < 0.001
Widow 2533 88.2 336 11.8 0.73 (0.65–0.81)  < 0.001
MSM 163 83.6 32 16.4 1.81 (0.77–1.54) 0.646
History of IDU 1260 86.7 194 13.3 1.13 (0.98–1.31) 0.099
History of sex work 319 82.2 69 17.8 1.24 (0.98–1.58) 0.074
History of transfusion 391 88.7 50 11.3 0.77 (0.58–1.02) 0.063
Economic migrant 357 82.3 77 17.7 1.63 (1.30–2.05)  < 0.001
History of imprisonment 304 87.9 42 12.1 1.02 (0.75–1.39) 0.889
History of displacement 56 86.2 9 13.8 1.27 (0.66–2.45) 0.472
Having HIV + partner 994 87.0 148 13.0 0.92 (0.78–1.08) 0.297
BMI < 18.5 kg/m3 4339 82.9 898 17.1 1.38 (1.25–1.53)  < 0.001
Baseline WHO stage
 1 6979 86.4 1096 13.6 Ref
 2 696 82.2 151 17.8 1.26 (1.06–1.49) 0.008
 3 6263 85.7 1041 14.3 0.91 (0.84–0.99) 0.033
 4 3602 86.2 578 13.8 0.83 (0.75–0.91)  < 0.001
Baseline CD4 > 500 cells/mL 530 84.1 100 15.9 1.64 (1.34–2.00)  < 0.001
Baseline Tuberculosis 5757 86.4 909 13.6 0.88 (0.81–0.95)  < 0.001
No ART regimen changes during observation time 4330 72.8 1664 27.2 6.60 (6.16–7.06)  < 0.001
History of low-level viremia 8032 81.5 1829 18.5 1.59 (1.49–1.70)  < 0.001
Frequency of low-level viremia
 0 13,649 88.6 1750 11.4 Ref
 1 6395 86.2 1028 13.8 1.15 (1.07–1.24)  < 0.001
  ≥ 2 1637 67.1 801 31.9 3.11 (2.86–3.38)  < 0.001
History of loss-to-follow-up 1837 75.3 603 24.7 1.80 (1.65–1.96)  < 0.001
Frequency of loss-to-follow-up
 0 19,844 87.0 2976 13.0 Ref
 1 1556 77.0 465 23.0 1.69 (1.53–1.86)  < 0.001
 2 214 67.3 104 32.7 2.28 (1.87–2.77)  < 0.001
  ≥ 3 67 66.3 34 33.7 2.32 (1.66–3.26)  < 0.001
Cumulative appointment delay ≥ 60 days 4809 80.0 1196 20.0 1.69 (1.58–1.81)  < 0.001
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other studies, which identified advanced HIV disease as 
a strong predictor of treatment failure [5, 14, 17, 38–40]. 
Almost 10% of our participants were LFU at least once, 
and the vast majority (86.8%) had been late for at least 
one appointment. This is in concordance with other stud-
ies showing temporary disengagement from care can be 
very common in these cohorts (11–77%) [21–25]. When 
LFU and appointment delay are not measured continu-
ously, but only at a given moment in time, the frequency 
of treatment interruptions is very likely to be underes-
timated [21]. Our study relied on a rigorously updated 
programme database with regards to visit dates, which 
allowed us to identify delay and treatment interruptions. 
The cumulative appointment delay was < 60  days for 
63% of the cohort. In the univariate analysis cumulative 
appointment delay ≥ 60  days was correlated with higher 
risk of virological failure (p < 0.001), but when controlling 
for other variables the association was not significant. 
However, having at least one single time point with treat-
ment interruption of at least 60  days while being LFU 
was associated with increased risk of failure. This is simi-
lar to findings from other contexts [5, 39]. Adding cumu-
lative appointment delay in the risk of virological failure 
analysis was not valuable in this cohort, but different cut-
off values for cumulative appointment delay or delay per 
year on ART could be explored in future analyses.
A systematic review reported that history of treatment 
change was associated with an approximately 2.5-fold 
higher risk of virological failure in cohorts in Myanmar 
and Malawi [14]. In our cohort, PLHIV who remained on 
the same first-line ART regimen during the study period 
were at a higher risk of failure. It is possible that previous 
reports used a different definition of “treatment change”. 
In our cohort, patients with treatment changes may have 
been followed up more closely, with better management 
of adverse events and possibly a lower risk of drug-drug 
interactions.
Increasing evidence shows that low-level viremia is 
associated with unfavorable treatment outcomes. A large 
multicentre cohort in South Africa detected low-level 
viremia in 23% of PLHIV, with risk of subsequent fail-
ure in this group observed as 2.6 times higher (95% CI 
2.5–2.6; p < 0.0001) than in PLHIV who did not experi-
ence low-level viremia [19]. In our study, 39% of patients 
had at least one episode of low-level viremia, and a his-
tory of low viremia was associated with an increased 
risk of treatment failure. A study from Sweden reported 
chronic low-level viremia in 31% of their population, with 
2.1 times higher (95% CI 1.3–3.6) risk of mortality when 
compared with PLHIV without a history of low-level 
viremia [20].
There is an effective and life-saving second-line ART 
regimen, but delayed switch is particularly problematic 
in patients with advanced HIV disease. Current recom-
mendations for the management of virological failure rely 
on a public health approach. Programmes in resource-
limited settings use a threshold of ≥ 1000 copies/mL to 
identify failure and recommend switching to second-line 
ART when virological failure is confirmed in a second 
sample [41]. Some have argued that in settings with no 
access to drug resistance testing, such approaches might 
delay introduction of effective and life-saving second-
line ART regimens and might increase risk of resistance 
accumulation, which in turn with further compromise 
effectiveness of second-line treatment; this would be par-
ticularly problematic in patients with advanced HIV dis-
ease and it has been argued that in some circumstances 
switching to second-line treatment could be considered 
in patients with a single VL showing viremia above 1000 
copies/mL [42].
Guidelines on virological monitoring and the manage-
ment of treatment failure have been changing over time 
[42–44]. In our study until 2016 most of our patients 
had a VL done based on immunological and/or clinical 
criteria. Only after 2012 did a threshold of VL ≥ 1000 
copies/mL become an indication for switching to second-
line ART. Nevertheless, in this study cohort since 2009 
61.5% of patients with viremia ≥ 1000 copies/mL received 
a follow-up VL. Virological failure was confirmed 
among 57.1% of those with a follow-up VL, with 66.5% 
of the latter being switched to second-line ART. The 
Table 3 Adjusted hazard ratios for virological failure among 
complete cases with more than 6 months of first-line ART and at 
least one VL test and complete data on key variables (n = 8,308)
*Adjusted Hazard Ratio adjusted for variables presented in the table and history 
of ever receiving following categories of regimens: zidovudine/lamivudine/
emtricitabine + abacavir/tenofovir;stavudine/zidovudine + lamivudine/
emtricitabine + efavirenz; stavudine/zidovudine + lamivudine/
emtricitabine + nevirapine; tenofovir/abacavir + lamivudine/
emtricitabine + efavirenz or tenofovir/abacavir + lamivudine/
emtricitabine + nevirapine; and time being on ART < or >  = 2 years since access 
to viral load monitoring 1 January 2009); interaction between sex work and 
gender and gender and being single included in the model
Variable aHR* 95% CI P-value
Female 0.89 0.76–1.04 0.147
Age at ART initiation > 19 years 0.66 0.53–0.83  < 0.001
Baseline CD4 500 cells/mL 1.23 0.96–1.59 0.094
Baseline tuberculosis 1.30 1.14–1.49  < 0.001
Married 0.90 0.76–1.06 0.187
Single 0.83 0.66–1.03 0.089
History of sex work 0.71 0.18–2.86 0.633
History of IDU 1.05 0.77–1.43 0.764
History of loss-to-follow-up 1.24 1.01–1.52 0.041
History of low viremia 1.60 1.42–1.81  < 0.001
Cumulative appointment delay >  = 60 days 0.94 0.79–1.12 0.473
No history of changing ART regimen 1.37 1.07–1.76 0.012
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implementation of VL monitoring in resource-limited 
settings is a challenge. A study from Swaziland reported 
an increase of follow-up VL coverage to 84% in recent 
years, however, the proportion of patients with con-
firmed virological failure switched to second-line ART 
remained low (43.2%) [45]. Similarly, in South Africa and 
Lesotho only 25–30% of patients in need were switched 
to second-line treatment in a timely manner [46, 47]. 
Even though enhanced adherence counselling has been 
reported as an effective strategy to identify those truly in 
need of second-line ART in settings with limited access 
to drug resistance testing, only 53.4% (95% CI 40.1–
66.8%) of those who received such counselling and were 
identified as in need of second-line ART were switched, 
according to a systematic review from 2019 [48]. A pre-
vious study from Myanmar highlights the importance 
of timely switching to second-line ART, as one-third of 
those who did not switch died or were LFU from care [5].
In short, routine VL monitoring reduces mortality 
when used together with adherence support [48] and a 
timely switch to effective treatment [49, 50], but ensur-
ing coverage of VL and second-line ART for those with 
a diagnosis of virological failure remains a huge chal-
lenge. When coverage is low, the overall benefit from VL 
scale-up might be lower than anticipated. To improve 
programme performance along the VL cascade, inno-
vative approaches, such as “mHealth” [51] or “nurse-
champions” [52] can be effective. Furthermore, it might 
be important to prioritize and differentiate VL testing in 
those at a higher risk of failure, in settings where barri-
ers for scale-up exist. For instance, the management of 
PLHIV who re-engage in care after being LFU requires 
more frequent VL monitoring [26] and possibly a faster 
switch to second-line treatment, especially if they present 
with clinical signs of advanced HIV disease. Consider-
ing the correlation between low-level viremia and treat-
ment failure [19, 53, 54] and mortality [20], the threshold 
of ≥ 1000 copies/mL for enrollment into enhanced adher-
ence support and switching to second-line ART may 
need to be revised. A more differentiated approach to VL 
monitoring, guided by the increasing body of evidence 
on predictors of virological failure and mortality among 
patients with low-level viremia and/or virological failure, 
may result in better outcomes for those most at risk.
Our study evaluated a large cohort with a long study 
period. It used real-life programme data with complete 
data on appointment delays, including LFU. However, 
28.6% of the cohort had no VL during the observation 
period and data for various baseline characteristics were 
incomplete, which resulted in only a part of our cohort 
being included in the final multivariable model. The 
resulting selection bias might lower the internal valid-
ity of our study results and reduce the generalizability of 
our study findings. The burden of virological failure was 
assessed by looking at the first episode of virological fail-
ure only, despite knowing that PLHIV transit from sup-
pressed to unsuppressed state multiple times during their 
time on ART. This might underestimate the total burden 
of failure in a cohort and multistate analysis of virological 
outcomes would be more appropriate. We did not inves-
tigate the reason why patients did not access VL, were 
delayed or LFU, or why switching to second-line ART 
was delayed. Further research on these topics is needed.
Conclusion
VL monitoring is an important tool to improve pro-
gramme outcomes. Suboptimal viral load cascade in 
resource-limited settings hampers the full potential of 
VL monitoring and it reduces its cost-effectiveness. Our 
study observed higher rates of virological failure among 
children and adolescents, in PLHIV with tuberculo-
sis co-infection and those with history of LFU or who 
remain on one treatment regimen. Those subgroups 
might need more frequent virological and more intensive 
clinical monitoring. Growing evidence on the risk fac-
tors for unfavourable virological and clinical outcomes, 
may suggest the refinement of a differentiated approach 
to VL monitoring in growing and aging HIV cohorts in 
resource-limited settings.
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